Sihuan Pharmaceutical Holdings Group ( (HK:0460) ) has issued an update.
Sihuan Pharmaceutical Holdings Group Ltd. announced its annual results for the year ended December 31, 2024, reporting a total revenue increase of 2.2% to RMB1,901.1 million. The company experienced significant growth in its medical aesthetics business, with a 65.4% rise in sales revenue, while its generic medicine business saw a decline due to centralized procurement and regulatory changes. The innovative medicine segment showed a substantial increase in revenue, attributed to the launch of Anaprazole Sodium. Despite these shifts, the company faced an operating loss of RMB138.1 million, primarily due to increased share-based payments.
More about Sihuan Pharmaceutical Holdings Group
Sihuan Pharmaceutical Holdings Group Ltd. is a company incorporated in Bermuda, operating in the pharmaceutical industry. The company focuses on medical aesthetics, generic medicines, and innovative medicines, with a market presence primarily in the People’s Republic of China.
YTD Price Performance: -2.00%
Technical Sentiment Signal: Strong Buy
Current Market Cap: $732M
See more data about 0460 stock on TipRanks’ Stock Analysis page.